Show simple item record

Regulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case study

dc.contributor.authorVitry, Agnes
dc.contributor.authorNguyen, Tuan
dc.contributor.authorEntwistle, Vikki
dc.contributor.authorRoughead, Elizabeth
dc.date.accessioned2015-10-21T11:32:02Z
dc.date.available2015-10-21T11:32:02Z
dc.date.issued2015-10-19
dc.identifier56969078
dc.identifiera2b3ae59-9b6d-4912-bc0e-1a6ccbcb74ba
dc.identifier84983167630
dc.identifier.citationVitry , A , Nguyen , T , Entwistle , V & Roughead , E 2015 , ' Regulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case study ' , Journal of Pharmaceutical Policy and Practice , vol. 8 , 25 . https://doi.org/10.1186/s40545-015-0046-2en
dc.identifier.otherORCID: /0000-0002-0856-4025/work/74327780
dc.identifier.urihttp://hdl.handle.net/2164/5095
dc.descriptionAcknowledgements Professor Elizabeth Roughead is funded by a Future Fellowship from the Australian Research Council. The views expressed are those of the authors, the sponsor had no role in the preparation of the manuscript.en
dc.format.extent11
dc.format.extent681038
dc.language.isoeng
dc.relation.ispartofJournal of Pharmaceutical Policy and Practiceen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectpharmaceutical policyen
dc.subjectmanaged entry agreementen
dc.subjectmedicine subsidizationen
dc.subjectcoverage with evidence developmenten
dc.subjectRS Pharmacy and materia medicaen
dc.subject.lccRSen
dc.titleRegulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doi10.1186/s40545-015-0046-2


Files in this item

Thumbnail
Name:
s40545_015_0046_2.pdf
Size:
665.0Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record